Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ADAGRASIB for Rectosigmoid cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where ADAGRASIB was used for Rectosigmoid cancer.

Most Reported Side Effects for ADAGRASIB

Side Effect Reports % Deaths Hosp.
Death 272 30.3% 258 21
Diarrhoea 113 12.6% 9 46
Hospitalisation 108 12.0% 7 108
Nausea 87 9.7% 13 47
Vomiting 79 8.8% 11 44
Off label use 70 7.8% 12 27
Asthenia 61 6.8% 10 39
Fatigue 51 5.7% 4 21
Decreased appetite 43 4.8% 4 20
Dehydration 35 3.9% 3 25
Dyspnoea 32 3.6% 7 18
Dizziness 27 3.0% 3 16
Acute kidney injury 26 2.9% 6 19
Weight decreased 24 2.7% 7 12
General physical health deterioration 19 2.1% 7 12

Other Indications for ADAGRASIB

Lung neoplasm malignant (388) Product used for unknown indication (189) Non-small cell lung cancer (92) Lung adenocarcinoma (42) Colon cancer (41) Lung adenocarcinoma stage iv (20) Non-small cell lung cancer metastatic (15) Bronchial carcinoma (13) Colorectal cancer (11) Colorectal cancer metastatic (9)

Other Drugs Used for Rectosigmoid cancer

CAPECITABINE (273) OXALIPLATIN (266) TIPIRACIL\TRIFLURIDINE (263) FLUOROURACIL (153) BEVACIZUMAB (134) PANITUMUMAB (93) LEUCOVORIN (84) REGORAFENIB (81) FRUQUINTINIB (71) IRINOTECAN (57)

Related Pages

ADAGRASIB Full Profile All Rectosigmoid cancer Drugs ADAGRASIB Demographics ADAGRASIB Timeline